Merck’s Lagevrio (molnupiravir) has not demonstrated a statistically significant reduction in the risk of COVID-19 infection after household exposure to another person who has COVID-19.

In a phase 3 study, the drug did not achieve the primary endpoint of prevention, although participants taking Lagevrio were 23.6 percent less likely to develop COVID-19 through day 14 compared to those taking placebo.

Merck said the prevention study results “do not impact the efficacy and safety data observed” in  the company’s phase 3 MOVe-OUT trial for the treatment of mild-to-moderate COVID-19.

Lagevrio is authorized by the FDA for the treatment of mild-to-moderate COVID-19 adult patients who are at high risk of progression to severe COVID-19.